01:37am Positive news for Ipsen's Iqirvo Zonebourse
01:12am Ipsen : IQIRVO® demonstrates statistically significant improvement in ALP normalization in patients with PBC in Phase IIIb ELSPIRE study PU
07-10 Ipsen - Dysport is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine AQ
07-09 Ipsen Reports Positive Topline Phase III Results for Dysport in Both Episodic and Chronic Migraine CI
07-09 Ipsen's Migraine Treatment Meets Primary Endpoints in Late-stage Trial MT
07-09 Dysport® is the first botulinum toxin to achieve positive topline Phase III results in both episodic and chronic migraine. GL
07-07 Ipsen - Half year statement - 2026 06 30 GL
07-07 AlphaValue/Baader Europe Cuts Ipsen Price Target Amid Future Patent Expiries, Mid-term Risks MT
07-06 IPSEN - Buy-back programme - Art 5 of MAR - Week 27- 2026 GL
07-06 Ipsen: Reassessing mid-term risks Alphavalue
07-06 BlackRock tops 5% stake in Ipsen Zonebourse
07-03 IPSEN - Buy-back programme - Art 5 of MAR - Week 26- 2026 GL
07-01 AlphaValue/Baader Europe Downgrades Ipsen to Add, Lifts PT MT
07-01 Oddo BHF still neutral on Ipsen after a new acquisition Zonebourse
07-01 Ipsen to Acquire Memo Therapeutics in Up to EUR700 Million Deal MT
07-01 Ipsen lines up another bolt-on acquisition Zonebourse
07-01 French biotech Ipsen to buy Memo Therapeutics for $230 million upfront RE
07-01 Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio GL
06-30 Ipsen S.A. entered into a definitive share purchase agreement to acquire Memo Therapeutics AG for over ?700 million. CI
06-30 Ipsen Extends Its Rally, Backed by Oddo BHF Zonebourse
06-29 Health Care Flat as Risk Appetite Rebounds - Health Care Roundup DJ
06-29 RBC Capital weighs in on Ipsen acquisition Zonebourse
06-29 French biotech company Ipsen to buy Kartos Therapeutics for $450 million RE
06-29 Ipsen strengthens its hematology franchise with the acquisition of Kartos Therapeutics Zonebourse
06-29 Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion MT
No results match your criteria